Plus Therapeutics drug gets FDA orphan designation

Plus Therapeutics has secured Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its drug REYOBIQ™, targeting pediatric malignant gliomas. This designation is a significant step, offering incentives for the development of treatments for rare diseases. It acknowledges the potential of REYOBIQ™ to address a critical unmet need in treating young patients with this aggressive form of brain cancer. The designation may expedite the drug's path through clinical trials and regulatory review.